2nd June, 2021
DCGI Chief VG Somani has taken a big step to speed up the ongoing vaccination program in India by issuing a notice. Under this, now the Drug Regulatory Body of India i.e. DGCI has withdrawn the conditions for bringing other foreign vaccines including the Covid-19 vaccine developed by Pfizer and Moderna to India and getting them tested again before use.
DCGI has said in its notice that vaccines that have received emergency use approval from the US FDA, or which have been approved by the World Health Organization for use in emergency services, will no longer be tested. In its notice, DCGI has also said that those vaccines will also be exempted from this trial, which have so far been applied on lakhs of people and who have benefited from it. Any such vaccine will no longer have to go through the process of trial before use.
In this notice, DCGI has been asked to expedite vaccination in view of the cases of corona infection in the country. It states that for this the vaccine will need to be imported from abroad. Along with this, DCGI has also said that for the supply of vaccine manufactured in the country, its production will need to be increased. According to the notice, the vaccine approved for emergency use by the US FDA, EMA, UK MHRA, PMDA Japan or the World Health Organization will not undergo trials, following the recommendations of NEGGVAC in view of the increasing demand for the vaccine in India. Let us tell you that in the latest notice, DCGI has made some changes in its old notice which was issued on 15 April.
It is worth noting that this step of DCGI will not only speed up the vaccination but will also help in controlling the epidemic. Let us tell you that due to the lack of vaccine in the country, there has been some interruption in the vaccination program. Due to this many vaccination centers have been closed. Many states have raised the demand for vaccine, while many have said that their vaccination centers are on the verge of closure.
To meet this shortcoming, India had approved the installation of Russia's Sputnik V vaccine as an emergency service. Its consignment has already arrived in India. However, to give vaccine to most of the population of the country, crores more doses will be needed. At the same time, there is a decrease in vaccine production in the country. One of the major reasons for this is the shortage of raw materials. In this regard, India has urged the US many times that the supply of raw materials for the vaccine should be uninterrupted.